{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T01:58:25Z","timestamp":1769911105409,"version":"3.49.0"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Bone Marrow Transplant"],"published-print":{"date-parts":[[2021,7]]},"DOI":"10.1038\/s41409-021-01215-y","type":"journal-article","created":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T09:06:39Z","timestamp":1612170399000},"page":"1603-1613","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Incidence and risk factors of hepatic veno-occlusive disease\/sinusoidal obstruction syndrome after allogeneic hematopoietic cell transplantation in adults with prophylactic ursodiol and intravenous heparin or prostaglandin E1"],"prefix":"10.1038","volume":"56","author":[{"given":"Jae-Ho","family":"Yoon","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gi June","family":"Min","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8826-4136","authenticated-orcid":false,"given":"Sung-Soo","family":"Park","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Silvia","family":"Park","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sung-Eun","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4524-6616","authenticated-orcid":false,"given":"Byung-Sik","family":"Cho","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ki-Seong","family":"Eom","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoo-Jin","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chang-Ki","family":"Min","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5429-4839","authenticated-orcid":false,"given":"Seok-Goo","family":"Cho","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3967-4267","authenticated-orcid":false,"given":"Dong-Wook","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jong Wook","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4098-3366","authenticated-orcid":false,"given":"Hee-Je","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9442-9814","authenticated-orcid":false,"given":"Seok","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,2,1]]},"reference":[{"key":"1215_CR1","doi-asserted-by":"publisher","first-page":"1361","DOI":"10.1038\/s41409-019-0492-6","volume":"54","author":"JH Yoon","year":"2019","unstructured":"Yoon JH, Yoo KH, Sung KW, Jung CW, Kim JS, Hahn SM, et al. Validation of treatment outcomes according to revised severity criteria from European Society for Blood and Marrow Transplantation (EBMT) for sinusoidal obstruction syndrome\/veno-occlusive disease (SOS\/VOD). Bone Marrow Transpl. 2019;54:1361\u20138. https:\/\/doi.org\/10.1038\/s41409-019-0492-6","journal-title":"Bone Marrow Transpl"},{"key":"1215_CR2","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/j.bbmt.2009.08.024","volume":"16","author":"JA Coppell","year":"2010","unstructured":"Coppell JA, Richardson PG, Soiffer R, Martin PL, Kernan NA, Chen A, et al. Hepatic veno-occlusive disease following stem cell transplantation: incidence, clinical course, and outcome. Biol Blood Marrow Transpl. 2010;16:157\u201368. https:\/\/doi.org\/10.1016\/j.bbmt.2009.08.024","journal-title":"Biol Blood Marrow Transpl"},{"key":"1215_CR3","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1038\/bmt.2009.349","volume":"45","author":"SH Lee","year":"2010","unstructured":"Lee SH, Yoo KH, Sung KW, Koo HH, Kwon YJ, Kwon MM, et al. Hepatic veno-occlusive disease in children after hematopoietic stem cell transplantation: incidence, risk factors, and outcome. Bone Marrow Transpl. 2010;45:1287\u201393. https:\/\/doi.org\/10.1038\/bmt.2009.349","journal-title":"Bone Marrow Transpl"},{"key":"1215_CR4","doi-asserted-by":"publisher","first-page":"1562","DOI":"10.1038\/bmt.2013.101","volume":"48","author":"JH Yoon","year":"2013","unstructured":"Yoon JH, Min WS, Kim HJ, Kim JH, Shin SH, Yahng SA, et al. Experiences of t-PA use in moderate-to-severe hepatic veno-occlusive disease after hematopoietic SCT: is it still reasonable to use t-PA? Bone Marrow Transpl. 2013;48:1562\u20138. https:\/\/doi.org\/10.1038\/bmt.2013.101","journal-title":"Bone Marrow Transpl"},{"key":"1215_CR5","doi-asserted-by":"publisher","first-page":"255","DOI":"10.7326\/0003-4819-118-4-199302150-00003","volume":"118","author":"GB McDonald","year":"1993","unstructured":"McDonald GB, Hinds MS, Fisher LD, Schoch HG, Wolford JL, Banaji M, et al. Veno-occlusive disease of the liver and multiorgan failure after bone marrow transplantation: a cohort study of 355 patients. Ann Intern Med. 1993;118:255\u201367.","journal-title":"Ann Intern Med"},{"key":"1215_CR6","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1097\/00062752-200311000-00010","volume":"10","author":"M Wadleigh","year":"2003","unstructured":"Wadleigh M, Ho V, Momtaz P, Richardson P. Hepatic veno-occlusive disease: pathogenesis, diagnosis and treatment. Curr Opin Hematol. 2003;10:451\u201362.","journal-title":"Curr Opin Hematol"},{"key":"1215_CR7","first-page":"3599","volume":"92","author":"E Carreras","year":"1998","unstructured":"Carreras E, Bertz H, Arcese W, Vernant JP, Tomas JF, Hagglund H, et al. Incidence and outcome of hepatic veno-occlusive disease after blood or marrow transplantation: a prospective cohort study of the European Group for Blood and Marrow Transplantation. European Group for Blood and Marrow Transplantation Chronic Leukemia Working Party. Blood. 1998;92:3599\u2013604.","journal-title":"Blood"},{"key":"1215_CR8","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1016\/S0140-6736(11)61938-7","volume":"379","author":"S Corbacioglu","year":"2012","unstructured":"Corbacioglu S, Cesaro S, Faraci M, Valteau-Couanet D, Gruhn B, Rovelli A, et al. Defibrotide for prophylaxis of hepatic veno-occlusive disease in paediatric haemopoietic stem-cell transplantation: an open-label, phase 3, randomised controlled trial. Lancet. 2012;379:1301\u20139. https:\/\/doi.org\/10.1016\/S0140-6736(11)61938-7","journal-title":"Lancet"},{"key":"1215_CR9","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1038\/bmt.2017.161","volume":"53","author":"S Corbacioglu","year":"2018","unstructured":"Corbacioglu S, Carreras E, Ansari M, Balduzzi A, Cesaro S, Dalle JH, et al. Diagnosis and severity criteria for sinusoidal obstruction syndrome\/veno-occlusive disease in pediatric patients: a new classification from the European society for blood and marrow transplantation. Bone Marrow Transpl. 2018;53:138\u201345. https:\/\/doi.org\/10.1038\/bmt.2017.161","journal-title":"Bone Marrow Transpl"},{"key":"1215_CR10","first-page":"1396","volume":"90","author":"S Cesaro","year":"2005","unstructured":"Cesaro S, Pillon M, Talenti E, Toffolutti T, Calore E, Tridello G, et al. A prospective survey on incidence, risk factors and therapy of hepatic veno-occlusive disease in children after hematopoietic stem cell transplantation. Haematologica. 2005;90:1396\u2013404. e-pub ahead of print 2005\/10\/13","journal-title":"Haematologica"},{"key":"1215_CR11","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.1038\/bmt.2014.168","volume":"49","author":"PD Tsirigotis","year":"2014","unstructured":"Tsirigotis PD, Resnick IB, Avni B, Grisariu S, Stepensky P, Or R, et al. Incidence and risk factors for moderate-to-severe veno-occlusive disease of the liver after allogeneic stem cell transplantation using a reduced intensity conditioning regimen. Bone Marrow Transpl. 2014;49:1389\u201392. https:\/\/doi.org\/10.1038\/bmt.2014.168","journal-title":"Bone Marrow Transpl"},{"key":"1215_CR12","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1016\/j.bbmt.2011.06.006","volume":"17","author":"E Carreras","year":"2011","unstructured":"Carreras E, Diaz-Beya M, Rosinol L, Martinez C, Fernandez-Aviles F, Rovira M. The incidence of veno-occlusive disease following allogeneic hematopoietic stem cell transplantation has diminished and the outcome improved over the last decade. Biol Blood Marrow Transpl. 2011;17:1713\u201320. https:\/\/doi.org\/10.1016\/j.bbmt.2011.06.006","journal-title":"Biol Blood Marrow Transpl"},{"key":"1215_CR13","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1038\/sj.bmt.1705528","volume":"38","author":"K Ramasamy","year":"2006","unstructured":"Ramasamy K, Lim ZY, Pagliuca A, Grundy R, Devereux S, Ho AY, et al. Incidence and management of hepatic venoocclusive disease in 237 patients undergoing reduced-intensity conditioning (RIC) haematopoietic stem cell transplantation (HSCT). Bone Marrow Transpl. 2006;38:823\u20134. https:\/\/doi.org\/10.1038\/sj.bmt.1705528","journal-title":"Bone Marrow Transpl"},{"key":"1215_CR14","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1200\/JCO.1993.11.2.304","volume":"11","author":"JP Radich","year":"1993","unstructured":"Radich JP, Sanders JE, Buckner CD, Martin PJ, Petersen FB, Bensinger W, et al. Second allogeneic marrow transplantation for patients with recurrent leukemia after initial transplant with total-body irradiation-containing regimens. J Clin Oncol. 1993;11:304\u201313. https:\/\/doi.org\/10.1200\/JCO.1993.11.2.304","journal-title":"J Clin Oncol"},{"key":"1215_CR15","doi-asserted-by":"publisher","first-page":"1720","DOI":"10.1016\/j.bbmt.2019.04.020","volume":"25","author":"DI Marks","year":"2019","unstructured":"Marks DI, Kebriaei P, Stelljes M, Gokbuget N, Kantarjian H, Advani AS, et al. Outcomes of allogeneic stem cell transplantation after inotuzumab ozogamicin treatment for relapsed or refractory acute lymphoblastic leukemia. Biol Blood Marrow Transpl. 2019;25:1720\u20139. https:\/\/doi.org\/10.1016\/j.bbmt.2019.04.020","journal-title":"Biol Blood Marrow Transpl"},{"key":"1215_CR16","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1056\/NEJMoa1509277","volume":"375","author":"HM Kantarjian","year":"2016","unstructured":"Kantarjian HM, DeAngelo DJ, Stelljes M, Martinelli G, Liedtke M, Stock W, et al. Inotuzumab Ozogamicin versus standard therapy for acute lymphoblastic leukemia. N. Engl J Med. 2016;375:740\u201353. https:\/\/doi.org\/10.1056\/NEJMoa1509277","journal-title":"N. Engl J Med"},{"key":"1215_CR17","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1038\/sj.bmt.1702854","volume":"27","author":"M Simon","year":"2001","unstructured":"Simon M, Hahn T, Ford LA, Anderson B, Swinnich D, Baer MR, et al. Retrospective multivariate analysis of hepatic veno-occlusive disease after blood or marrow transplantation: possible beneficial use of low molecular weight heparin. Bone Marrow Transpl. 2001;27:627\u201333. https:\/\/doi.org\/10.1038\/sj.bmt.1702854","journal-title":"Bone Marrow Transpl"},{"key":"1215_CR18","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1038\/sj.bmt.1705297","volume":"37","author":"H Imran","year":"2006","unstructured":"Imran H, Tleyjeh IM, Zirakzadeh A, Rodriguez V, Khan SP. Use of prophylactic anticoagulation and the risk of hepatic veno-occlusive disease in patients undergoing hematopoietic stem cell transplantation: a systematic review and meta-analysis. Bone Marrow Transpl. 2006;37:677\u201386. https:\/\/doi.org\/10.1038\/sj.bmt.1705297","journal-title":"Bone Marrow Transpl"},{"key":"1215_CR19","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1111\/j.1365-2141.1990.tb02583.x","volume":"74","author":"E Gluckman","year":"1990","unstructured":"Gluckman E, Jolivet I, Scrobohaci ML, Devergie A, Traineau R, Bourdeau-Esperou H, et al. Use of prostaglandin E1 for prevention of liver veno-occlusive disease in leukaemic patients treated by allogeneic bone marrow transplantation. Br J Haematol. 1990;74:277\u201381. https:\/\/doi.org\/10.1111\/j.1365-2141.1990.tb02583.x","journal-title":"Br J Haematol"},{"key":"1215_CR20","doi-asserted-by":"publisher","first-page":"2834","DOI":"10.1182\/blood.V79.11.2834.bloodjournal79112834","volume":"79","author":"M Attal","year":"1992","unstructured":"Attal M, Huguet F, Rubie H, Huynh A, Charlet JP, Payen JL, et al. Prevention of hepatic veno-occlusive disease after bone marrow transplantation by continuous infusion of low-dose heparin: a prospective, randomized trial. Blood. 1992;79:2834\u201340.","journal-title":"Blood"},{"key":"1215_CR21","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1016\/j.bbmt.2006.09.012","volume":"13","author":"J Tay","year":"2007","unstructured":"Tay J, Tinmouth A, Fergusson D, Huebsch L, Allan DS. Systematic review of controlled clinical trials on the use of ursodeoxycholic acid for the prevention of hepatic veno-occlusive disease in hematopoietic stem cell transplantation. Biol Blood Marrow Transpl. 2007;13:206\u201317. https:\/\/doi.org\/10.1016\/j.bbmt.2006.09.012","journal-title":"Biol Blood Marrow Transpl"},{"key":"1215_CR22","doi-asserted-by":"publisher","first-page":"3664","DOI":"10.1182\/blood-2014-01-552984","volume":"123","author":"P Armand","year":"2014","unstructured":"Armand P, Kim HT, Logan BR, Wang Z, Alyea EP, Kalaycio ME, et al. Validation and refinement of the Disease Risk Index for allogeneic stem cell transplantation. Blood. 2014;123:3664\u201371. https:\/\/doi.org\/10.1182\/blood-2014-01-552984","journal-title":"Blood"},{"key":"1215_CR23","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1002\/cncr.31874","volume":"125","author":"JH Yoon","year":"2019","unstructured":"Yoon JH, Min GJ, Park SS, Jeon YW, Lee SE, Cho BS, et al. Minimal residual disease-based long-term efficacy of reduced-intensity conditioning versus myeloablative conditioning for adult Philadelphia-positive acute lymphoblastic leukemia. Cancer. 2019;125:873\u201383. https:\/\/doi.org\/10.1002\/cncr.31874","journal-title":"Cancer"},{"key":"1215_CR24","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1007\/s12185-010-0649-y","volume":"92","author":"SE Lee","year":"2010","unstructured":"Lee SE, Kim HJ, Min WS, Cho BS, Eom KS, Kim YJ, et al. Favorable outcomes of intravenous busulfan, fludarabine, and 400 cGy total body irradiation-based reduced-intensity conditioning allogeneic stem cell transplantation for acute myelogenous leukemia with old age and\/or co-morbidities. Int J Hematol. 2010;92:342\u201350. https:\/\/doi.org\/10.1007\/s12185-010-0649-y","journal-title":"Int J Hematol"},{"key":"1215_CR25","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1111\/j.1600-0609.2011.01697.x","volume":"87","author":"SE Lee","year":"2011","unstructured":"Lee SE, Kim YJ, Yahng SA, Cho BS, Eom KS, Lee S, et al. Survival benefits from reduced-intensity conditioning in allogeneic stem cell transplantation for young lower-risk MDS patients without significant comorbidities. Eur J Haematol. 2011;87:510\u201320. https:\/\/doi.org\/10.1111\/j.1600-0609.2011.01697.x","journal-title":"Eur J Haematol"},{"key":"1215_CR26","doi-asserted-by":"publisher","first-page":"1456","DOI":"10.1038\/bmt.2016.171","volume":"51","author":"SH Shin","year":"2016","unstructured":"Shin SH, Jeon YW, Yoon JH, Yahng SA, Lee SE, Cho BS, et al. Comparable outcomes between younger (40 years) and older (>40 years) adult patients with severe aplastic anemia after HLA-matched sibling stem cell transplantation using fludarabine-based conditioning. Bone Marrow Transpl. 2016;51:1456\u201363. https:\/\/doi.org\/10.1038\/bmt.2016.171","journal-title":"Bone Marrow Transpl"},{"key":"1215_CR27","doi-asserted-by":"publisher","first-page":"1368","DOI":"10.1002\/ajh.25257","volume":"93","author":"SE Lee","year":"2018","unstructured":"Lee SE, Park SS, Jeon YW, Yoon JH, Cho BS, Eom KS, et al. Optimal conditioning regimen for haplo-identical stem cell transplantation in adult patients with acquired severe aplastic anemia: prospective de-escalation study of TBI and ATG dose. Am J Hematol. 2018;93:1368\u201375. https:\/\/doi.org\/10.1002\/ajh.25257","journal-title":"Am J Hematol"},{"key":"1215_CR28","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1002\/hep.1840040121","volume":"4","author":"GB McDonald","year":"1984","unstructured":"McDonald GB, Sharma P, Matthews DE, Shulman HM, Thomas ED. Venocclusive disease of the liver after bone marrow transplantation: diagnosis, incidence, and predisposing factors. Hepatology. 1984;4:116\u201322.","journal-title":"Hepatology"},{"key":"1215_CR29","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1097\/00007890-198712000-00011","volume":"44","author":"RJ Jones","year":"1987","unstructured":"Jones RJ, Lee KS, Beschorner WE, Vogel VG, Grochow LB, Braine HG, et al. Venoocclusive disease of the liver following bone marrow transplantation. Transplantation. 1987;44:778\u201383. e-pub ahead of print 1987\/12\/01","journal-title":"Transplantation"},{"key":"1215_CR30","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1038\/bmt.2015.52","volume":"50","author":"M Mohty","year":"2015","unstructured":"Mohty M, Malard F, Abecassis M, Aerts E, Alaskar AS, Aljurf M, et al. Sinusoidal obstruction syndrome\/veno-occlusive disease: current situation and perspectives-a position statement from the European Society for Blood and Marrow Transplantation (EBMT). Bone Marrow Transpl. 2015;50:781\u20139. https:\/\/doi.org\/10.1038\/bmt.2015.52","journal-title":"Bone Marrow Transpl"},{"key":"1215_CR31","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1038\/bmt.2016.130","volume":"51","author":"M Mohty","year":"2016","unstructured":"Mohty M, Malard F, Abecassis M, Aerts E, Alaskar AS, Aljurf M, et al. Revised diagnosis and severity criteria for sinusoidal obstruction syndrome\/veno-occlusive disease in adult patients: a new classification from the European Society for Blood and Marrow Transplantation. Bone Marrow Transpl. 2016;51:906\u201312. https:\/\/doi.org\/10.1038\/bmt.2016.130","journal-title":"Bone Marrow Transpl"},{"key":"1215_CR32","doi-asserted-by":"publisher","first-page":"1656","DOI":"10.1182\/blood-2015-10-676924","volume":"127","author":"PG Richardson","year":"2016","unstructured":"Richardson PG, Riches ML, Kernan NA, Brochstein JA, Mineishi S, Termuhlen AM, et al. Phase 3 trial of defibrotide for the treatment of severe veno-occlusive disease and multi-organ failure. Blood. 2016;127:1656\u201365. https:\/\/doi.org\/10.1182\/blood-2015-10-676924","journal-title":"Blood"},{"key":"1215_CR33","doi-asserted-by":"publisher","first-page":"1495","DOI":"10.1182\/bloodadvances.2017008375","volume":"2","author":"PG Richardson","year":"2018","unstructured":"Richardson PG, Carreras E, Iacobelli M, Nejadnik B. The use of defibrotide in blood and marrow transplantation. Blood Adv. 2018;2:1495\u2013509. https:\/\/doi.org\/10.1182\/bloodadvances.2017008375","journal-title":"Blood Adv"},{"key":"1215_CR34","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1080\/17512433.2018.1421943","volume":"11","author":"PG Richardson","year":"2018","unstructured":"Richardson PG, Triplett BM, Ho VT, Chao N, Dignan FL, Maglio M, et al. Defibrotide sodium for the treatment of hepatic veno-occlusive disease\/sinusoidal obstruction syndrome. Exp Rev Clin Pharmacol. 2018;11:113\u201324. https:\/\/doi.org\/10.1080\/17512433.2018.1421943","journal-title":"Exp Rev Clin Pharmacol"},{"key":"1215_CR35","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1080\/19371910903070333","volume":"25","author":"DS Kim","year":"2010","unstructured":"Kim DS. Introduction: health of the health care system in Korea. Soc Work Public Health. 2010;25:127\u201341. https:\/\/doi.org\/10.1080\/19371910903070333","journal-title":"Soc Work Public Health"},{"key":"1215_CR36","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1038\/bmt.2015.283","volume":"51","author":"K Yakushijin","year":"2016","unstructured":"Yakushijin K, Atsuta Y, Doki N, Yokota A, Kanamori H, Miyamoto T, et al. Sinusoidal obstruction syndrome after allogeneic hematopoietic stem cell transplantation: Incidence, risk factors and outcomes. Bone Marrow Transpl. 2016;51:403\u20139. https:\/\/doi.org\/10.1038\/bmt.2015.283","journal-title":"Bone Marrow Transpl"},{"issue":"12 Pt 1","key":"1215_CR37","doi-asserted-by":"publisher","first-page":"975","DOI":"10.7326\/0003-4819-128-12_part_1-199806150-00002","volume":"128","author":"JH Essell","year":"1998","unstructured":"Essell JH, Schroeder MT, Harman GS, Halvorson R, Lew V, Callander N, et al. Ursodiol prophylaxis against hepatic complications of allogeneic bone marrow transplantation. A randomized, double-blind, placebo-controlled trial. Ann Intern Med. 1998;128(12 Pt 1):975\u201381. https:\/\/doi.org\/10.7326\/0003-4819-128-12_part_1-199806150-00002","journal-title":"Ann Intern Med"},{"key":"1215_CR38","doi-asserted-by":"publisher","first-page":"1977","DOI":"10.1182\/blood-2001-12-0159","volume":"100","author":"T Ruutu","year":"2002","unstructured":"Ruutu T, Eriksson B, Remes K, Juvonen E, Volin L, Remberger M, et al. Ursodeoxycholic acid for the prevention of hepatic complications in allogeneic stem cell transplantation. Blood. 2002;100:1977\u201383. https:\/\/doi.org\/10.1182\/blood-2001-12-0159","journal-title":"Blood"},{"key":"1215_CR39","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1002\/(SICI)1096-8652(200005)64:1<32::AID-AJH6>3.0.CO;2-N","volume":"64","author":"K Ohashi","year":"2000","unstructured":"Ohashi K, Tanabe J, Watanabe R, Tanaka T, Sakamaki H, Maruta A, et al. The Japanese multicenter open randomized trial of ursodeoxycholic acid prophylaxis for hepatic veno-occlusive disease after stem cell transplantation. Am J Hematol. 2000;64:32\u201338. https:\/\/doi.org\/10.1002\/(sici)1096-8652(200005)64:1<32::aid-ajh6>3.0.co;2-n","journal-title":"Am J Hematol"},{"key":"1215_CR40","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1038\/sj.bmt.1703342","volume":"29","author":"SH Park","year":"2002","unstructured":"Park SH, Lee MH, Lee H, Kim HS, Kim K, Kim WS, et al. A randomized trial of heparin plus ursodiol vs. heparin alone to prevent hepatic veno-occlusive disease after hematopoietic stem cell transplantation. Bone Marrow Transpl. 2002;29:137\u201343. https:\/\/doi.org\/10.1038\/sj.bmt.1703342","journal-title":"Bone Marrow Transpl"},{"key":"1215_CR41","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1111\/j.1600-0609.1991.tb01859.x","volume":"47","author":"L Marsa-Vila","year":"1991","unstructured":"Marsa-Vila L, Gorin NC, Laporte JP, Labopin M, Dupuy-Montbrun MC, Fouillard L, et al. Prophylactic heparin does not prevent liver veno-occlusive disease following autologous bone marrow transplantation. Eur J Haematol. 1991;47:346\u201354. https:\/\/doi.org\/10.1111\/j.1600-0609.1991.tb01859.x","journal-title":"Eur J Haematol"},{"key":"1215_CR42","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1097\/00007890-199604150-00014","volume":"61","author":"R Or","year":"1996","unstructured":"Or R, Nagler A, Shpilberg O, Elad S, Naparstek E, Kapelushnik J, et al. Low molecular weight heparin for the prevention of veno-occlusive disease of the liver in bone marrow transplantation patients. Transplantation. 1996;61:1067\u201371. https:\/\/doi.org\/10.1097\/00007890-199604150-00014","journal-title":"Transplantation"},{"key":"1215_CR43","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1111\/j.1365-2141.1993.tb03152.x","volume":"84","author":"SI Bearman","year":"1993","unstructured":"Bearman SI, Shen DD, Hinds MS, Hill HA, McDonald GB. A phase I\/II study of prostaglandin E1 for the prevention of hepatic venocclusive disease after bone marrow transplantation. Br J Haematol. 1993;84:724\u201330. https:\/\/doi.org\/10.1111\/j.1365-2141.1993.tb03152.x","journal-title":"Br J Haematol"},{"key":"1215_CR44","doi-asserted-by":"publisher","first-page":"897","DOI":"10.3346\/jkms.2006.21.5.897","volume":"21","author":"JS Song","year":"2006","unstructured":"Song JS, Seo JJ, Moon HN, Ghim T, Im HJ. Prophylactic low-dose heparin or prostaglandin E1 may prevent severe veno-occlusive disease of the liver after allogeneic hematopoietic stem cell transplantation in Korean children. J Korean Med Sci. 2006;21:897\u2013903. https:\/\/doi.org\/10.3346\/jkms.2006.21.5.897","journal-title":"J Korean Med Sci"},{"key":"1215_CR45","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1111\/bjh.14727","volume":"178","author":"PG Richardson","year":"2017","unstructured":"Richardson PG, Smith AR, Triplett BM, Kernan NA, Grupp SA, Antin JH, et al. Earlier defibrotide initiation post-diagnosis of veno-occlusive disease\/sinusoidal obstruction syndrome improves Day +100 survival following haematopoietic stem cell transplantation. Br J Haematol. 2017;178:112\u20138. https:\/\/doi.org\/10.1111\/bjh.14727","journal-title":"Br J Haematol"},{"key":"1215_CR46","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1016\/j.bbmt.2017.03.008","volume":"23","author":"PG Richardson","year":"2017","unstructured":"Richardson PG, Smith AR, Triplett BM, Kernan NA, Grupp SA, Antin JH, et al. Defibrotide for patients with hepatic veno-occlusive disease\/sinusoidal obstruction syndrome: interim results from a treatment IND study. Biol Blood Marrow Transpl. 2017;23:997\u20131004. https:\/\/doi.org\/10.1016\/j.bbmt.2017.03.008","journal-title":"Biol Blood Marrow Transpl"}],"container-title":["Bone Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41409-021-01215-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41409-021-01215-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41409-021-01215-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T21:18:37Z","timestamp":1684617517000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41409-021-01215-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,1]]},"references-count":46,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2021,7]]}},"alternative-id":["1215"],"URL":"https:\/\/doi.org\/10.1038\/s41409-021-01215-y","relation":{},"ISSN":["0268-3369","1476-5365"],"issn-type":[{"value":"0268-3369","type":"print"},{"value":"1476-5365","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2,1]]},"assertion":[{"value":"22 September 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 December 2020","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 January 2021","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 February 2021","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Written informed consent was obtained at the stage of transplantation in all patients.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"This research was conducted in accordance with the Institutional Review Board guidelines of the Catholic Medical Center (KC20RISI0132\/199).","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}}]}}